Kiniksa Pharmaceuticals International (KNSA) EBIT Margin (2021 - 2026)

Kiniksa Pharmaceuticals International has reported EBIT Margin for 6 years, with the latest figure at 13.66% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 403.0% year-over-year to 13.66%; the trailing twelve-month figure through Mar 2026 stood at 5.08% (up 836.0% YoY), and the FY2025 full-year result was 3.29%, up 1407.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 13.66%, up from 17.38% in the prior quarter.
• The five-year high for EBIT Margin was 46.82% in Q3 2022, with the low at 72.44% in Q1 2022.
• Historically, EBIT Margin has averaged 9.32% across 5 years, with a median of 4.41% in 2023.
• Annual changes were most pronounced in 2022 — EBIT Margin soared 45461 bps — and 2023, when it slumped 6312 bps.
• Kiniksa Pharmaceuticals International's EBIT Margin stood at 4.08% in 2022, then surged by 102 bps to 0.1% in 2023, then tumbled by 16315 bps to 15.75% in 2024, then decreased by 10 bps to 17.38% in 2025, then surged by 179 bps to 13.66% in 2026.
• The last three EBIT Margin figures came in at 13.66% (Q1 2026), 17.38% (Q4 2025), and 13.28% (Q3 2025), per Business Quant data.